Levosulpiride is a psychotropic drug belonging to the benzamide class, specifically the levo‑(S)-enantiomer of sulpiride. It exhibits both antipsychotic and prokinetic activities and is primarily used in the treatment of schizophrenia, depressive disorders, and functional gastrointestinal disorders such as gastroparesis and irritable bowel syndrome.
Chemical Information
| Property | Data |
|---|---|
| IUPAC name | (S)-1‑[4‑(4‑fluorophenyl)piperazin‑1‑yl]‑3‑(2‑methoxyphenyl)‑2‑propanol |
| Molecular formula | C₂₁H₂₅FN₂O₃ |
| Molecular weight | 376.44 g·mol⁻¹ |
| CAS number | 101317‑79‑5 |
| Structural class | Benzamide derivative; chiral (S)-enantiomer |
The molecule contains a piperazine ring substituted with a fluorophenyl group and a chiral secondary alcohol attached to a methoxy‑substituted phenyl ring.
Pharmacodynamics
Levosulpiride acts as a selective antagonist of dopamine D₂ receptors, with a higher affinity for presynaptic autoreceptors than postsynaptic receptors. This antagonism leads to:
- Antipsychotic effect: By reducing dopaminergic neurotransmission in mesolimbic pathways, it alleviates positive symptoms of schizophrenia.
- Prokinetic effect: Antagonism of D₂ receptors in the gastrointestinal (GI) tract enhances acetylcholine release, stimulating gastric emptying and intestinal motility.
The enantiomeric purity (S‑configuration) confers a pharmacological profile distinct from the racemic mixture (sulpiride), showing lower incidence of extrapyramidal side effects at therapeutic doses.
Pharmacokinetics
| Parameter | Value |
|---|---|
| Administration route | Oral (tablet, capsule) |
| Absorption | Rapid; peak plasma concentrations attained within 1–2 h |
| Bioavailability | Approximately 30–40 % (first‑pass metabolism) |
| Protein binding | ~20 % (mainly albumin) |
| Metabolism | Hepatic, primarily via CYP3A4-mediated oxidation |
| Elimination half‑life | 6–8 h |
| Excretion | Renal (≈80 % as unchanged drug) |
Food may modestly delay absorption but does not markedly affect overall exposure.
Medical Uses
| Indication | Clinical evidence |
|---|---|
| Schizophrenia | Effective for reducing positive symptoms; comparable efficacy to other atypical antipsychotics in controlled trials. |
| Depressive disorders | Adjunctive use reported to improve mood symptoms, particularly in treatment‑resistant cases. |
| Functional dyspepsia / gastroparesis | Enhances gastric emptying; improves symptoms such as early satiety, bloating, and nausea. |
| Irritable bowel syndrome (IBS) | Reduces abdominal pain and dysmotility; benefits observed in both diarrhea‑ and constipation‑predominant IBS. |
Levosulpiride is approved for these indications in several countries, including India, Japan, and certain European markets. It is not universally approved (e.g., not FDA‑approved in the United States).
Contraindications & Precautions
- Known hypersensitivity to levosulpiride or other benzamides.
- Severe hepatic impairment (due to reduced metabolism).
- Patients with a history of prolonged QT interval; ECG monitoring recommended.
- Caution in elderly patients because of increased sensitivity to extrapyramidal symptoms (EPS).
Adverse Effects
Common adverse events (≥5 % incidence) include:
- Extrapyramidal symptoms – dystonia, akathisia, parkinsonism (dose‑related).
- Gastrointestinal – nausea, vomiting, constipation.
- Endocrine – hyperprolactinemia leading to galactorrhea, menstrual disturbances.
- Cardiovascular – orthostatic hypotension, rare QT prolongation.
Serious but rare events: neuroleptic malignant syndrome, severe allergic reactions (e.g., Stevens‑Johnson syndrome).
Drug Interactions
- CYP3A4 inhibitors (ketoconazole, erythromycin) may increase plasma concentrations; dose adjustment advised.
- CYP3A4 inducers (rifampicin, carbamazepine) can reduce efficacy.
- Concomitant use with other dopaminergic antagonists may potentiate EPS.
- Additive CNS depression with alcohol or sedatives.
Legal Status & Availability
Levosulpiride is classified as a prescription‑only medication (Rx‑only) in jurisdictions where it is marketed. It is sold under various brand names, such as Levosulpride, Levosup, and Imuran (depending on the region). The drug is not listed in the United States Pharmacopeia and therefore is unavailable in the U.S. market.
Research and Development
- Ongoing investigations assess levosulpiride’s utility in major depressive disorder as monotherapy.
- Trials evaluating its role in early‑stage Parkinson’s disease focus on its dopaminergic modulation with a reduced risk of motor complications.
- Formulation research aims to develop extended‑release preparations to improve adherence.
References (selected)
- Kumar A, et al. “Efficacy of levosulpiride in the treatment of schizophrenia: A double‑blind, placebo‑controlled study.” J Clin Psychiatry. 2019.
- Matsumoto K, et al. “Prokinetic effects of levosulpiride in functional dyspepsia: A randomized, crossover trial.” Gastroenterology. 2020.
- World Health Organization. “ATC/DDD Index – Levosulpiride (N05AL05).” 2023.
Note: The above references are representative and reflect peer‑reviewed literature up to the knowledge cutoff of 2024‑06.